July 31, 2023 02:12 PM EDTUpdated 03:08 PM
FDA+

FDA ap­proves GSK's Jem­per­li for front­line use in cer­tain ad­vanced en­dome­tri­al can­cers

Zachary Brennan

Senior Editor

GSK’s new can­cer drug Jem­per­li (dostar­limab) won an FDA ap­proval on Mon­day, al­most two months ahead of its PDU­FA date, for use in cer­tain front­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times